Press Releases
Date picker
Category
Results per page
Kancera reports results from clinical Phase I study and strategy for continued development of KAND567
Kancera AB (publ) hereby reports results from a Phase I study in healthy subjects with the immunoregulating drug candidate KAND567. The study shows that KAND567 is safe and well-tolerated up…
Kancera reports that clinical Phase I study has been completed in the Fractalkine project
Kancera AB (publ) reports that the Phase I study in the Fractalkine project has been completed in accordance with study protocols. In the study, drug characteristics, safety and tolerability have…
Kancera acquires additional rights to the Fractalkine project
Kancera AB (publ) has previously announced that the company controls patents and rights to the Fractalkine project, including KAND567, in all diseases except lung diseases. Agreements with AstraZeneca AB and…
Kancera performs the second partial payment for the Fractalkine project
Regulatory
According to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain…
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 30th September 2017
Regulatory
PERIOD 1 JAN - 30 SEPT 2017 IN BRIEF• R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million…
KANCERA PROVIDES AN OPERATIONAL UPDATE FOR THE ROR PROJECT
Kancera hereby reports that the company's ROR inhibitor KAN0441571 effectively eliminates ROR1-bearing leukemic cells in a mouse model of human chronic lymphocytic leukemia.
Kancera and Recipharm collaborate to manufacture clinical trial supply
Kancera, a development company focused on cancer therapy and Recipharm, a leading contract development and manufacturing organisation (CDMO), have signed a contract for the development and manufacture of the pharmaceutical…
Kancera announces start of Phase 1 Multiple Ascending Dose Trial of KAND567
Kancera today launches the second part of the ongoing clinical Phase I study of KAND567. During this part of the study, KAND567 is administered to groups of healthy subjects in…
INTERIM REPORT FOR KANCERA AB (publ) JANUARI 1ST – JUNE 30TH 2017
This is a translation from the original report published in Swedish August 22nd 2017.
Kancera announces approval for the start of clinical trial of KAND567
The Medical Ethics Committee (METC) at the University Medical Center in Groningen, The Netherlands, has approved the start of clinical Phase I study of KAND567. The first dose to humans…